Evaluation of Cognitive Function of Patients Treated With Sunitinib or Sorafenib
In this study we will focus on subjective and objective cognitive dysfunctioning in patients
with metastatic cancer, treated with sunitinib or sorafenib. In our own clinical practice a
substantial part of our patients that are treated with targeted therapies directed against
VEGF, mention that they have problems with concentrating and that their memory function is
decreased. Relatives sometimes point out that the behaviour of the patient is slightly
different than before starting the VEGF (Vascular Endothelial Growth Factor) inhibition.
Pre-clinical studies show that VEGF influences growth and recovery of neurons.
Observational Model: Case-Only, Time Perspective: Prospective
C.M.L. van Herpen, Md PhD
University Medical Centre Nijmegen
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)